Despite extensive research over the years, acute GvHD (aGvHD) affects the majority of patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT), and up to 50% can develop clinically significant (grades4II) aGvHD. The incidence is slightly lower in patients given reduced intensity conditioning regimens. 1 However, severe aGvHD in this context occurs in up to 20% of patients. Evaluation of factors predisposing to aGvHD has clearly demonstrated the role of increased conditioning-related toxicity in its etiology. 2 On the other hand, the contribution of methotrexate (MTX) as GvHD prophylaxis for the development of mucositis cannot be overlooked. 3 This antiproliferant agent impairs mucosal regeneration after conditioning-related injury, thereby prolonging and worsening oral mucositis. Severe oral mucositis occurs in up to 75% of myeloablative allo-HSCT recipients, often within the first week after conditioning therapy.
Frequently, a short course of IV MTX (given on days +1, +3, +6 and +11 after HSCT) is combined with a 6-month tapered course of cyclosporine for GvHD prophylaxis. 4 Clinical trials have demonstrated a survival advantage in patients who received the combination of cyclosporine (CSA) plus MTX compared with either drug alone. 5, 6 Despite the advances leading to novel aGvHD detection, prophylaxis and treatment method, significant challenges to eradicate aGvHD remain. There is no consensus on which drugs and schedules for prevention of GvHD are best and clinical practice varies by institution. 7 Further, it has not been studied if omission of the day +1 of MTX has a negative effect on outcome in terms of frequency of GvHD and survival. Therefore, we retrospectively reviewed the experience at our institution to address this question in patients receiving MTX (omitting day +1) plus cyclosporine A (CSA) as GvHD prophylaxis.
Ninety five consecutive patients who underwent allo-HSCT from 2000 to September 2016, and received MTX as immunosuppressive prophylaxis were included. All patients received three doses of MTX, always excluding day +1.
The data set used for this retrospective study was derived from patients' information collected from the Transplantation Program records, which include the transplantation record forms, containing all the information regarding the transplant procedure. Also, hospital official medical records, including electronic records and imaging, were revised. The Institutional Review Board approved the usage of patients' information for this retrospective study.
The following conditioning regimens were used: (1) Reduced busulfan and cyclophosphamide (BUCY) 2 conditioning regimen consisted of: busulfan 12 mg/kg, divided in 4 days (3 mg/kg/day, ORAL, during days − 7, − 6, − 5 and − 4), and Cyclophosphamide (Cy), IV, 80 mg/kg, divided in 2 days (40 mg/kg/day, during days − 3 and − 2), (2) BUCY 2 consisted of: busulfan 16 mg/kg and Cy 120 mg/kg, (3) Cy 50 mg/kg divided in 4 days, (4) Cy 50 mg/kg divided in 4 days and ATG 30 mg/kg divided in 3 days, (5) fludarabine 30 mg/msq for 5 days, Cy 50 mg/kg/day divided in 4 days and ATG 10 mg/kg/day divided in 4 days.
MTX was administered IV either 10 mg/m 2 during days +3, +6, +11 or 15 mg/m 2 during day +3 and 10 mg/m 2 during days +6 and +11. CsA was administered IV, 1.5 mg/kg/12 h, during day − 1 and adjusted according to serum levels (200-300 ng/μL) until 2005, afterwards; CsA was administered orally, 10 mg/kg during day − 1, and 5 mg/kg starting day 0, adjusting according to therapeutic monitoring. Acute and chronic GvHD were graded around the time of diagnosis according to the established criteria.
Toxicity was evaluated according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.0), which classifies each toxicity as grades I-IV.
Neutrophil engraftment was considered as ANC ⩾ 0.5 × 10 9 /L in the first day of 3 consecutive days. Platelet engraftment was defined as a platelet count ⩾ 20 × 10 9 /L during 3 consecutive days without transfusions.
Progression-free survival was established as the length of time after transplantation until relapse. Overall survival was defined as time from transplantation until death from any cause.
Continuous variables were described by medians and intervals, and categorical variables by frequencies and proportions. The probability of developing acute GvHD or chronic GvHD was depicted by calculating the cumulative incidence as competing risks. Overall survival and relapse-free survival were estimated using the Kaplan-Meier method. All analyses were carried out using IBM-SPSS-Statistics, version 21 (IBM, Armonk, NY, USA).
The study group consisted of 95 patients (55% male) who had a median age of 31 years (range, 16-62). None of the patients were given MTX on day +1. Overall patients' characteristics are shown in Table 1 . Most of the patients received myeloablative conditioning regimens: reduced BUCY 2 (n = 71, 74%) and BUCY 2 (n = 2, 2%). The median days for infection development were 7 (range 0-36). The most common symptom of infection was neutropenic fever (44%), but only in 38% of the patients was a germ isolated. Most of the patients, 83% (n = 79), presented acute toxicity after the conditioning regimen, of whom 76% (n = 60) corresponded to superior mucositis (31.6% grade III-IV). Nineteen patients presented inferior mucositis (24%) (9.5% grade III-IV).
From the entire cohort, only fifteen patients (16%) developed acute GvHD, 8.4% grades I-II and 7.3% grades III-IV (Figure 1) . Skin was the most affected site (n = 11, 73%), followed by liver (n = 10, 67%) and intestine (n = 5, 33%). Thirty patients (32%) presented chronic GvHD, which was limited in 73%. Ten-year overall survival was 59% and the 10-year relapse-free survival was 68%.
Allo-HSCT can be limited given its mortality and high incidence of acute (14-70%) and chronic GvHD (70-80% with PBSC and 40-50% with steady-state bone marrow (SS-BM)), 8 which can potentially lead to lethal complications and an impairment in quality of life. It is not clear which drugs and schedules for prevention of GvHD are optimum and whether the effects of these drugs differ. The combination of MTX and CSA has been widely adopted as the preferred regimen for prevention of GvHD due to its superior efficacy compared with single agent MTX or CSA. Since 1986, 9 the combination of CSA and shortcourse MTX has resulted in marked improvement in survival as a result of decreased acute GvHD. Studies done before the introduction of the short-course MTX regimen compared it with longer courses (until day +100) of weekly MTX, but failed to show benefit for prolonged MTX. 10 Since then, several modifications of this regimen have been further explored. Deeg et al.
2 noted that MTX (10 mg/m 2 ) given on days +1, +3 and +6 did not result in higher rates of acute GvHD compared with historically reported rates. Some retrospective studies have found an increase in the incidence of aGvHD when omitting the day +11 MTX dose, however this difference has not been statistically significant. 11, 12 On the other hand, Bensinger et al. 13 compared MTX schedules whether they were prescribed for 3 or 4 days. They found that the relative effect of PBSC and BM on disease-free and overall survival was significantly different between the subgroups of trials, defined by whether the administration of day +11 MTX was part of the protocol. The difference was due primarily to a significantly lower rate of relapse and relapserelated deaths among recipients of PBSC in the four dose MTX trials. 13 Our results did not show an increased incidence of acute GvHD as a result of day +1 omission of MTX. The incidence of aGvHD in our cohort was 16% (7.3% grades III-IV), which is lower than the reported literature either omitting day +11 of MTX or not. This could be related to the conditioning regimen used in most of the hematological malignancies (reduced BUCY 2). Also, G-CSF-primed bone marrow (G-BM) was used in 79% of the patients, which is already known for reducing the incidence of acute and chronic GvHD when compared with PBSC.
14 Moreover, other involved factors could have been younger age of patients, relatively few female to male transplant and the use of matched related donors.
Chronic GvHD was presented in 32% of our patients, which compares with the reported literature, 15 with similar survivals compared with the previously reported studies.
Summarizing, our data propose that the administration of day +1 MTX as GvHD prophylaxis might not be necessary. However, the main limitation of our study is the lack of a control group, given its retrospective design making it necessary that further prospective studies comparing the two groups test our observations.
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